| Literature DB >> 35645817 |
Zi-Wei Zhou1,2, Hui-Zhi Long1,2, Shuo-Guo Xu1,2, Feng-Jiao Li1,2, Yan Cheng1,2, Hong-Yu Luo1,2, Li-Chen Gao1,2.
Abstract
Inflammation is a protective response of the body to an irritant. When an inflammatory response occurs, immune cells are recruited to the injury, eliminating the irritation. The excessive inflammatory response can cause harm to the organism. Inflammation has been found to contribute to cervical cancer if there is a problem with the regulation of inflammatory response. Cervical cancer is one of the most common malignant tumors globally, and the incidence tends to be younger. The harm of cervical cancer cannot be ignored. The standard treatments for cervical cancer include surgery, radiotherapy and chemotherapy. However, the prognosis for this treatment is poor, so it is urgent to find a safer and more effective treatment. Natural products are considered excellent candidates for the treatment of cervical cancer. In this review, we first describe the mechanisms by which inflammation induces cervical cancer. Subsequently, we highlight natural products that can treat cervical cancer through inflammatory pathways. We also introduce natural products for the treatment of cervical cancer in clinical trials. Finally, methods to improve the anticancer properties of natural products were added, and the development status of natural products was discussed.Entities:
Keywords: HPV; cervical cancer; inflammatory; natural products; therapeutic
Year: 2022 PMID: 35645817 PMCID: PMC9136176 DOI: 10.3389/fphar.2022.899208
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
FIGURE 1The process by which HPV infected cells becomes cancerous. The process by which HPV infected cells becomes cancerous. HPV virus particles are released when HPV infected cells undergo lysis. At this point, immune cells are recruited by virus particles and release pro-inflammatory cytokines. Inflammation will persists if the virus particles are not completely removed in time. This could cause HPV infected cells to become cancerous.
FIGURE 2Signaling pathways in the initial stage of cervical cancer cells. NF-κB is activated by pro-inflammatory cytokines such as IL-1β. NF-κB can not only change cytosine into thymine, but also induce CDA expression, thereby inducing gene mutation. The accumulation of inflammatory cells allows ROS to accumulate. The buildup of ROS could cause DNA damage. HPV E6 oncoprotein can inhibit GSH and CAT. ROS is further accumulated.
FIGURE 3Signaling pathways in the development stage of cervical cancer cells. E7 oncoproteins binds to the PRB-E2F complex, a step that separates E2F from pRb. In the case of high E2F expression, cells will pass the G1/S phase and pRb will eventually be degraded by the proteasome. The STAT3 signaling pathway can be activated by IL-6 to promote cell proliferation which can also be induced by HIF-1α, E5 can inhibit the expression of p21WAF1, thus promoting the separation of E2F from pRb, and regulate STAT3 by regulating EGFR.
Therapeutic potential of natural products based on inflammation in cervical cancer.
| Name |
| Mechanism | Dose/time-effect | Ref |
|---|---|---|---|---|
| Colchicine | CaSKi and HeLa cells | Decrease the expression of HPV 16 E6/E7 mRNA and protein, increase | Dose-effect |
|
| Piperine | HeLa cells, mice xenograft models | Reduce the expression of p65, decreased the expression of p-STAT3, NF-κB, and Bcl-2 in HeLa cells, while the activities of Bax, Bid, Caspase and PARP were increased | Dose-effect |
|
| Neferine | HeLa and SiHa cells | Increase the intracellular reactive oxygen species (ROS) | Dose-effect |
|
| Berberine | HeLa cells | Decrease the express of HPV 18 E6/E7, cyclin and NF-κβ. inhibit AP-1 group activation | Dose-effect | ( |
|
| ||||
| Icaritin | HeLa cells | Increase the expression of ROS, the number of DNA fractures, raise the expression of Bax and Caspase 3 and 9 | Dose-effect |
|
| Morusin | Human cervical CSCs | Decrease the expression of NF-κB, p65, and Bcl-2, and increased the levels of Bax and Caspase-3 | Dose-effect |
|
| Wogonin | SiHa and CaSki cells | Decrease the express of HPV 18 E6/E7, cleave poly ADP ribose polymerase | Dose-effect |
|
| Kaempferol-7-O-b-D-glucoside | HeLa cells | Reduce the nuclear translocation of NF-κB, upregulate the expression of Bax and down-regulate Bcl-2 | Time-effect, dose-effect |
|
| Fisetin | SiHa and CaSki cells | Inhibit the p38MAPK-dependent NF-κB signaling pathway | Dose-effect |
|
| Tanshinone IIA | CaSki cells | Decrease in HPV16 E6 and E7 protein levels | Time-effect, dose-effect |
|
| Emodin | SiHa cells, C33A | Inhibit the NO-,O2- and p-Akt activation, decrease HOCl/OCL- | Dose-effect |
|
| Eugenol | HeLa and SiHa cells | Up-regulate the expression of PARP, Bax, Caspase-3 and ROS, down-regulate the expression of Bcl-2 | Time-effect |
|
| Ethyl acetate extracts isolated from Pistacia vera L | CaSki cells | Down-regulate the expressions of TNF, Bcl-2, IAP and TRAF | Time-effect, dose-effect |
|
| Praeruptorin B | HeLa and SiHa cells | Down-regulate NF-κB, MMP-2 and -9 | Dose-effect |
|
| Baicalein | HeLa cells | Inhibit the IL-8, phosphorylation of NF-κB and I-κBα, blocking the TNF-α induced nuclear ectopia of p65 | Dose-effect | ( |
|
| ||||
| Fisetin | SiHa and CaSki | Inhibit the phosphorylation of P38/MAPK, affecting NF-κB and inhibiting nuclear translocation | Dose-effect |
|
| Luteolin | HeLa cells | Inhibit the activation of NF-κB by inhibiting TNF-α, and enhance the activity of JNK | Time-effect, dose-effect |
|
| Naringin | HeLa cells | Decrease NF-κB and COX-2 | Time-effect, dose-effect |
|
| Puerarin | U14 cervical cancer mice | Increase the activity of IL-2 and superoxide dismutase (SOD) | Time-effect |
|
| Triphala | HeLa cells | Inhibit the phosphorylation of NF-κB, decrease the expression of cyclin D1, and increased the expression of p53 | Dose-effect |
|
| Artesunate | HeLa cells | Inhibit NF-κB | Time-effect, dose-effect |
|
| HeLa and CaSki cells | Inhibit the expression of COX-2 | Dose-effect |
| |
| Curcumin | HeLa, CaSki and SiHa cells | Inhibit the expression of NF-κB, COX-2 and INOS | Dose-effect |
|
| EGCG | HeLa and Siha cells | Inhibit the activation of NF-κB, the expression of COX-2 | Dose-effect | ( |
|
| ||||
| Regulate the number of ROS | Time-effect. dose-effect |
| ||
| Quercetin | SiHa and HeLa cells | Inhibits the binding of the oncoprotein E6 to E6AP | Dose-effect | ( |
|
| ||||
| Resveratrol | HeLa cells | Inhibiting NF-κB and MMP9 expression | Dese-effect |
|
| Kaempferol | C33A,CaSki, HeLa and SiHa cells | Inhibit nuclear heterotopic of NF-κB, promote cell cycle arrest in G2/M phase | Time-effect |
|
| Morin | HeLa cells | Decrease NF-κB mRNA expression, increases ROS expression | Dose-effect | ( |
|
| ||||
| Rutin | K14-HPV16 mice | Reduce the expression of COX-2 and the leukocytes invasion | Time-effect, dose-effect | ( |
|
| ||||
|
| ||||
| Salvianolic Acid B | HeLa cells | Reduce the expression level of TGF | Time-effect, dose-effect |
|
| Praeruptorin-B | HeLa and Siha cells | Down-regulated the expression of NF-κB, MMP-2 and MMP-9 | Dose-effect |
|